title: Not every patient with multiple sclerosis should be treated at time of diagnosis.
authors.affiliation: Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
authors.forename: Sean J
authors.initials: SJ
authors.lastname: Pittock
authors.forename: Brian G
authors.initials: BG
authors.lastname: Weinshenker
authors.forename: John H
authors.initials: JH
authors.lastname: Noseworthy
authors.forename: Claudia F
authors.initials: CF
authors.lastname: Lucchinetti
authors.forename: Mark
authors.initials: M
authors.lastname: Keegan
authors.forename: Dean M
authors.initials: DM
authors.lastname: Wingerchuk
authors.forename: Jonathan
authors.initials: J
authors.lastname: Carter
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Shuster
authors.forename: Moses
authors.initials: M
authors.lastname: Rodriguez
mesh_terms: D002985:Clinical Protocols / Q000592:standards*; D004185:Disability Evaluation; D018450:Disease Progression; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000009:adverse effects / Q000276:immunology; D008279:Magnetic Resonance Imaging / Q000592:standards; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000628:therapy*; D018579:Patient Selection; D055502:Secondary Prevention; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016899:Interferon-beta; D000068556:Interferon beta-1a